Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRCN-1023 in Amyotrophic Lateral Sclerosis
NCT07674667Phase 2Recruiting
- Sponsor
- Trace Neuroscience
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 3
01
Overview
A Phase 2 trial of TRCN-1023 in amyotrophic lateral sclerosis (ALS), sponsored by Trace Neuroscience. Started Aug 2026; status: recruiting.
02
Drugs
TRCN-1023
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07674667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674667.